从开发者的角度强调医疗创新的开发、资助和报销方面的挑战

Dr. Nira Hariyatie Hartani, Muhammad Talal Ahmad,
{"title":"从开发者的角度强调医疗创新的开发、资助和报销方面的挑战","authors":"Dr. Nira Hariyatie Hartani, Muhammad Talal Ahmad,","doi":"10.5912/jcb1530","DOIUrl":null,"url":null,"abstract":"Healthcare system is an essential system for any nation as it is responsible for maintaining the health of the individuals and public. However, the outbreak of different viral diseases such as influenza, covid-19 etc. has encouraged medical research in different developing and developed countries. Similarly, in Malaysia, different public and private research centers and biotechnology firms are being promoted to develop new and innovative medical drugs and equipment. However, different challenges are faced by the developers in promoting the development and innovations of medical commodities. Thus, this study was conducted to investigate different challenges in the development, funding, and reimbursement of medical innovations in Malaysia. For this purpose, semi-structured interviews were conducted with 7 developers from different public research and development (R&D) centers and biotechnology firms in Malaysia. After the interviews were conducted, their edited transcription was obtained, and thematic analysis was conducted, and different themes and sub-themes were formulated. The results obtained from this study showed that the lack of innovative environment, strategic compliances and effective funding structure negatively influences medical innovations in Malaysia. It has also been observed that poor reimbursement practices and policies and lack of pricing strategies by the Malaysian government impacts the ROI of the associated firms and developers. Thus, it has been recommended that mega-funds and reimbursement policies should be promoted to overcome these challenges in medical innovations.","PeriodicalId":88541,"journal":{"name":"Journal of commercial biotechnology","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Highlighting the Challenges in the Development, Funding, and Reimbursement of Medical Innovations from a Developer Perspective\",\"authors\":\"Dr. Nira Hariyatie Hartani, Muhammad Talal Ahmad,\",\"doi\":\"10.5912/jcb1530\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Healthcare system is an essential system for any nation as it is responsible for maintaining the health of the individuals and public. However, the outbreak of different viral diseases such as influenza, covid-19 etc. has encouraged medical research in different developing and developed countries. Similarly, in Malaysia, different public and private research centers and biotechnology firms are being promoted to develop new and innovative medical drugs and equipment. However, different challenges are faced by the developers in promoting the development and innovations of medical commodities. Thus, this study was conducted to investigate different challenges in the development, funding, and reimbursement of medical innovations in Malaysia. For this purpose, semi-structured interviews were conducted with 7 developers from different public research and development (R&D) centers and biotechnology firms in Malaysia. After the interviews were conducted, their edited transcription was obtained, and thematic analysis was conducted, and different themes and sub-themes were formulated. The results obtained from this study showed that the lack of innovative environment, strategic compliances and effective funding structure negatively influences medical innovations in Malaysia. It has also been observed that poor reimbursement practices and policies and lack of pricing strategies by the Malaysian government impacts the ROI of the associated firms and developers. Thus, it has been recommended that mega-funds and reimbursement policies should be promoted to overcome these challenges in medical innovations.\",\"PeriodicalId\":88541,\"journal\":{\"name\":\"Journal of commercial biotechnology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-02-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of commercial biotechnology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5912/jcb1530\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of commercial biotechnology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5912/jcb1530","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

医疗保健系统是任何国家必不可少的系统,因为它负责维护个人和公众的健康。然而,不同的病毒性疾病,如流感、covid-19等的爆发,鼓励了不同发展中国家和发达国家的医学研究。同样,在马来西亚,正在推动不同的公共和私营研究中心和生物技术公司开发新的和创新的医疗药品和设备。然而,在推动医疗商品开发创新的过程中,开发商面临着不同的挑战。因此,本研究旨在调查马来西亚医疗创新在发展、资助和报销方面面临的不同挑战。为此,我们对来自马来西亚不同公共研发中心和生物技术公司的7位开发人员进行了半结构化访谈。访谈结束后,获得访谈内容的编辑抄本,并进行主题分析,制定不同的主题和子主题。从这项研究中获得的结果表明,缺乏创新环境,战略合规和有效的融资结构对马来西亚的医疗创新产生了负面影响。还观察到,马来西亚政府不良的报销做法和政策以及缺乏定价策略影响了相关公司和开发商的投资回报率。因此,有人建议,应促进大型基金和报销政策,以克服医疗创新方面的这些挑战。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Highlighting the Challenges in the Development, Funding, and Reimbursement of Medical Innovations from a Developer Perspective
Healthcare system is an essential system for any nation as it is responsible for maintaining the health of the individuals and public. However, the outbreak of different viral diseases such as influenza, covid-19 etc. has encouraged medical research in different developing and developed countries. Similarly, in Malaysia, different public and private research centers and biotechnology firms are being promoted to develop new and innovative medical drugs and equipment. However, different challenges are faced by the developers in promoting the development and innovations of medical commodities. Thus, this study was conducted to investigate different challenges in the development, funding, and reimbursement of medical innovations in Malaysia. For this purpose, semi-structured interviews were conducted with 7 developers from different public research and development (R&D) centers and biotechnology firms in Malaysia. After the interviews were conducted, their edited transcription was obtained, and thematic analysis was conducted, and different themes and sub-themes were formulated. The results obtained from this study showed that the lack of innovative environment, strategic compliances and effective funding structure negatively influences medical innovations in Malaysia. It has also been observed that poor reimbursement practices and policies and lack of pricing strategies by the Malaysian government impacts the ROI of the associated firms and developers. Thus, it has been recommended that mega-funds and reimbursement policies should be promoted to overcome these challenges in medical innovations.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
1.20
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信